Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Post-Mkt 12-05 16:58:51 EST

3.70

+0.02

+0.54%

盘后3.70

+0.000.00%

16:10 EST

High3.80	Low3.66	Vol623.24K
Open3.72	D1 Closing3.68	Amplitude3.80%
Mkt Cap316.68M	Tradable Cap167.05M	Total Shares85.59M
T/O2.31M	T/O Rate1.38%	Tradable Shares45.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":3.7,"timestamp":1764968400000,"preClose":3.68,"halted":0,"volume":623244,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"16:10 EST","volume":1905,"amount":7048.5,"timestamp":1764969004508},"delay":0,"floatShares":45149399,"shares":85590392,"eps":-1.953372,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"12-05 16:58:51 EST","open":3.72,"high":3.8,"low":3.66,"amount":2311155.1561,"amplitude":0.038043,"askPrice":3.79,"askSize":30,"bidPrice":3.57,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-1.953372,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764982800000},"marketStatusCode":4,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":3.68,"preHourTrading":{"tag":"盘前","latestPrice":3.69,"preClose":3.68,"latestTime":"09:00 EST","volume":4736,"amount":17475.84,"timestamp":1764943215094},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"16:10 EST","volume":1905,"amount":7048.5,"timestamp":1764969004508},"volumeRatio":0.335826,"impliedVol":1.6717,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2584926815","title":"Larimar Therapeutics Q3 Net Income USD -47.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926815","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926815?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570317,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Larimar Therapeutics Q3 operating expenses USD 49.499 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:50.457 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD9Y0qxd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581095673","title":"Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095673?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:10","pubTimestamp":1762434619,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Radnet (RDNT – Research Report), Palvella Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-radnet-rdnt-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-radnet-rdnt-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XLV","LABU","RDNT","BK4585","LU2065731478.USD","HCSG","PVLA","LRMR","XBI","BK4196","LU0128526141.USD","BK4588","BK4139","LU0029874061.USD","BK4581"],"gpt_icon":0},{"id":"2581243717","title":"Larimar Therapeutics Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581243717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581243717?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:17","pubTimestamp":1762345076,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q3 net loss widensOverviewLarimar reports Q3 net loss of $47.7 mln, driven by increased R&D expensesCompany modifies nomlabofusp dosing to reduce anaphylaxis riskBLA submission fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0KW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581721810","title":"BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721810","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721810?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344050,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million\n\n\nNov 05 (Reuters) - Larimar Therapeutics Q3 operating expenses USD 49.499 million.\n\nQ3 basic EPS USD -0.61\nQ3 income from operations USD -49.499 million\nQ3 EPS USD -0.61","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581777729","title":"Larimar Therapeutics Q3 Basic EPS USD -0.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581777729?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581724964","title":"Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724964?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2577515077","title":"Larimar Therapeutics Inc  expected to post a loss of 40 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2577515077","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577515077?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:22","pubTimestamp":1761308525,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of40cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nL8N3W518F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2573940067","title":"Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573940067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573940067?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:36","pubTimestamp":1759923401,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Larimar Therapeutics today. The company’s shares closed yesterday at $4.72. Lee covers...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"gpt_icon":0},{"id":"2572637585","title":"Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2572637585","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572637585?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:55","pubTimestamp":1759528545,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics recently announced positive data from its long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in patients with Friedreich's Ataxia, alongside an update on its development program.\nThis milestone highlights progress in advancing novel treatments for a rare neurological disease, capturing interest among rare disease and biotech stakeholders.\nWe’ll explore how the encouraging clinical results for nomlabofusp are influencing Larimar...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/do-positive-friedreichs-ataxia-study-results-shift-larimar-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/do-positive-friedreichs-ataxia-study-results-shift-larimar-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2572512595","title":"Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2572512595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572512595?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:25","pubTimestamp":1759407904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nAZN4LSBVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2571349298","title":"Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349298?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-larimar-therapeutics-lrmr-inventiva-iva-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-larimar-therapeutics-lrmr-inventiva-iva-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","BK4137","LRMR","BK4581","BK4588","HCSG","BK4585","BK4139","XBI","BK4112","IVA"],"gpt_icon":0},{"id":"2571811316","title":"U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech","url":"https://stock-news.laohu8.com/highlight/detail?id=2571811316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571811316?lang=en_us&edition=fundamental","pubTime":"2025-09-30 15:01","pubTimestamp":1759215714,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, SemtechSept 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Electron","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH0GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STZ","SMTC","IMVT","BK4548","UBER","NUVB","SAM","LU0943347566.SGD","EA","COLD","IE00BMPRXN33.USD","IE00BLSP4452.SGD","FTAI","CSX","PRGS","MATX","LU1548497426.USD","LU2552382058.USD","MTN","CCL","SN","LU0689472784.USD","BK4139","LRMR","BK4543","ETSY","SG9999018857.SGD","WMB","ASO","CC","BK4598","TSYW.SI","PSTL","LU0170899867.USD","CCL.UK","CUZ","TAP","LYFT","LU2896262040.SGD","LU0208291251.USD","KALA","TMUS","IE0034235303.USD","IE00B3T34201.USD","ACHC","LU1983260115.SGD","BK4171"],"gpt_icon":1},{"id":"2571108362","title":"Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2571108362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571108362?lang=en_us&edition=fundamental","pubTime":"2025-09-30 08:15","pubTimestamp":1759191311,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Catherine Novack from JonesTrading maintained a Buy rating on Larimar Therapeutics, with a price target of $7.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jonestrading-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jonestrading-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2571464364","title":"Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571464364","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571464364?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:45","pubTimestamp":1759189510,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joori Park reiterated a Buy rating on Larimar Therapeutics today and set a price target of $25.00. The company’s shares cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"gpt_icon":0},{"id":"2571351154","title":"Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2571351154","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571351154?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:05","pubTimestamp":1759169100,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics, Inc.  is currently at $3.62, down $1.47 or 28.85%. --On pace for largest percent decrease since May 15, 2023, when it fell 29.05%. --Down 99.41% from its all-time closing high of $616.08 on March 19, 2015. --Down 44.66% from 52 weeks ago , when it closed at $6.55. --Up 111.99% from its 52-week closing low of $1.71 on April 8, 2025. --Traded as low as $3.10; lowest intraday level since July 7, 2025, when it hit $3.01. --Down 39.16% at today's intraday low; largest intraday percent decrease since Dec. 16, 2024, when it fell as much as 51.22%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LRMR","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2571358366","title":"Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2571358366","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571358366?lang=en_us&edition=fundamental","pubTime":"2025-09-29 23:20","pubTimestamp":1759159200,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/29/Scientific-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/29/Scientific-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47920098/larimar-therapeutics-stock-falls-after-patients-report-allergic-reaction-in-pivotal-study","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47920098/larimar-therapeutics-stock-falls-after-patients-report-allergic-reaction-in-pivotal-study","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4130","LU1169590202.USD","BK4023","BK4218","LU1169589451.USD","PK","FA","LRMR","PD","BK4139","BK4181","LENZ","BK4539","BK4535","BK4007"],"gpt_icon":0},{"id":"2571362183","title":"BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2571362183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571362183?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:01","pubTimestamp":1759150890,"startTime":"0","endTime":"0","summary":"BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug** Shares of Larimar Therapeutics LRMR.O fall 31% to $3.50 premarket on safety concerns about its experimental drug, nomlabofusp, after data from a long-term study** Drug was being tested for Friedreich's ataxia, a rare genetic disorder that causes progressive damage to the nervous system** Seven participants experienced anaphylaxis within the first 6 weeks of dosing and were withdrawn from the study, co says** Anaphylaxis is a sudden and severe allergic reaction that can cause breathing problems, swelling and a drop in blood pressure** \"The major downside is that we continue to see anaphylaxis\" - Jones Trading analyst Catherine Novack** As of last close, stock up 31% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG0U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2571387438","title":"BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387438","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387438?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:19","pubTimestamp":1759144746,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s AtaxiaSept 29 (Reuters) - Larimar Therapeutics Inc LRMR.O:LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUAMH4DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":1},{"id":"2571387908","title":"Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387908?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:15","pubTimestamp":1759144543,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG0MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2571701387","title":"Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2571701387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571701387?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:15","pubTimestamp":1759144542,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-announces-25-mg-50-mg-data-from-ol-study-of-nomlabofusp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-announces-25-mg-50-mg-data-from-ol-study-of-nomlabofusp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":0.0425},{"period":"1month","weight":-0.0316},{"period":"3month","weight":-0.066},{"period":"6month","weight":0.3731},{"period":"1year","weight":-0.3947},{"period":"ytd","weight":-0.0491}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.102481},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052852},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.145103},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.028256},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.091938},{"month":6,"riseRate":0.545455,"avgChangeRate":0.006336},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021968},{"month":8,"riseRate":0.5,"avgChangeRate":0.081374},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.047589}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}